FDA grants Matrix tentative approval under PEPFAR for Atazanavir Sulfate Capsules ANDA

Links shared publicly online about this topic.

824
total visits

FDA grants Matrix tentative approval under PEPFAR for Atazanavir Sulfate Capsules ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Atazanavir Sulfate Capsules, 150 mg and 300 mg. This product will be eligible for purchase outside the U.S. in certain developing countries.

View full resource at news-medical.net

Tags: Emergency, AIDS, HIV Medication, Drug, FDA, Reyataz, First Aid and Emergency